Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).


Options:
A: Change in Vascular Inflammation (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Vascular Inflammation (52 weeks of adalimumab treatment); Change in Cardiometabolic Biomarker - Total Cholesterol (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Cardiometabolic Biomarker - Cholesterol Efflux (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Cardiometabolic Biomarker - Low-density Lipoprotein Particle (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Cardiometabolic Biomarker - High-density Lipoprotein Particle (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Cardiometabolic Biomarker - Log Insulin (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Cardiometabolic Biomarker - Log Adiponectin (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Cardiometabolic Biomarker - Log Leptin (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Cardiometabolic Biomarker - Log C-reactive Protein (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Cardiometabolic Biomarker - Log Tumor Necrosis Factor-Alpha (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Cardiometabolic Biomarker - Log Interleukin 6 (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Cardiometabolic Biomarker - GlycA (52 weeks (continuation group) or 64 weeks (crossover group)); Change in Cardiometabolic Biomarkers: - Total Cholesterol (52 weeks of adalimumab treatment); Change in Cardiometabolic Biomarker - Cholesterol Efflux (52 weeks of adalimumab treatment); Change in Cardiometabolic Biomarker - Low-density Lipoprotein Particle (52 weeks of adalimumab treatment); Change in Cardiometabolic Biomarker - High-density Lipoprotein Particle (52 weeks of adalimumab treatment); Change in Cardiometabolic Biomarker - Log Insulin (52 weeks of adalimumab treatment); Change in Cardiometabolic Biomarker - Log Adiponectin (52 weeks of adalimumab treatment); Change in Cardiometabolic Biomarker - Log Leptin (52 weeks of adalimumab treatment); Change in Cardiometabolic Biomarker - Log C-reactive Protein (52 weeks of adalimumab treatment); Change in Cardiometabolic Biomarker - Log Tumor Necrosis Factor-Alpha (52 weeks of adalimumab treatment); Change in Cardiometabolic Biomarker - Log Interleukin 6 (52 weeks of adalimumab treatment); Change in Cardiometabolic Biomarker - GlycA (52 weeks of adalimumab treatment)
B: The Efficacy of Three Induction Regimens of AIN457 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque-type Psoriasis With Respect to PASI 75 Achievement After 12 Weeks of Treatment, Compared to Placebo. (13 weeks)
C: N/A
D: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A) (Week 16); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A) (Week 16)

Answer: B